Top Medications Used to Treat Kidney (Renal Cell Cancer)
This article discusses the top medications used to treat kidney cancer.02/25/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 25, 2019 Category: Urology & Nephrology Source Type: news
Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma Axitinib as an Adjuvant Treatment of Renal Cell Carcinoma
Does the VEGF inhibitor axitinib reduce risk of recurrence in patients with locoregional RCC post nephrectomy?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Being overweight in adolescence may increase kidney cancer risk later in life
(Wiley) Being overweight has been linked with a higher risk of developing a form of kidney cancer called renal cell carcinoma (RCC) among adults, but it's unclear if this risk is present during adolescence. In an International Journal of Cancer study of adolescents who were followed for 37 years, researchers observed a trend for higher RCC risk with increasing body mass index during adolescence, where one-unit increase in body mass index conferred a six percent increased risk of RCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2019 Category: Cancer & Oncology Source Type: news
Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC
First-line treatment with the anti-PD-1 immunotherapy pembrolizumab plus the VEGF-targeted tyrosine-kinase inhibitor axitinib extended overall survival and progression-free survival in patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib, in the phase 3 KEYNOTE-426 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 21, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC
In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non –clear cell renal cell carcinoma (RCC).02/20/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 20, 2019 Category: Urology & Nephrology Source Type: news
Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
Two large trials show benefits for pembrolizumab - axitinib and avelumab - axitinib versus sunitinib (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 20, 2019 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Journal, Source Type: news
Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
WEDNESDAY, Feb. 20, 2019 -- For first-line therapy of metastatic renal cell carcinoma, pembrolizumab plus axitinib and avelumab plus axitinib both show improved survival versus sunitinib, according to two studies published online Feb. 16 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 20, 2019 Category: Pharmaceuticals Source Type: news
' Exciting Times' With Immunotherapy for Kidney Cancer'Exciting Times' With Immunotherapy for Kidney Cancer
New combinations with immunotherapy are going to change the standard of care in metastatic renal cell carcinoma, but questions remain, and there are technicalities to consider, according to some experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 19, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.02/19/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 19, 2019 Category: Urology & Nephrology Source Type: news
ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma
During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news
ASCO GU 2019: Genetic Evolution of Metastatic Renal Cell Cancer
At ASCO GU in San Francisco, Dr. Samra Turajlic discussed the evolution of metastatic renal cell carcinoma.02/18/2019 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 18, 2019 Category: Urology & Nephrology Source Type: news
Pembrolizumab Plus Axitinib vs Standard Treatment For mRCC
Treatment with pembrolizumab plus axitinib improved response and survival compared with sunitinib in patients with advanced, or metastatic clear-cell renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
New Standard of Care for Metastatic Renal Cell Carcinoma New Standard of Care for Metastatic Renal Cell Carcinoma
Combination treatment with pembrolizumab and axitinib significantly improved survival outcomes as compared with sunitinib.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
